Canlyniadau Chwilio - Dominik Paul Modest

Mireinio'r Canlyniadau
  1. 1
    Prevalence of <i>KRAS</i> G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review

    Prevalence of <i>KRAS</i> G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review gan John H. Strickler, Takayuki Yoshino, Kendall Stevinson, C. Eichinger, Christina Giannopoulou, Marko Rehn, Dominik Paul Modest

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

    Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials gan Clemens Gießen, Ruediger P. Laubender, Donna P. Ankerst, Sebastian Stintzing, Dominik Paul Modest, Ulrich Mansmann, Volker Heinemann

    Cyhoeddwyd 2012
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial

    Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AI... gan Dominik Paul Modest, Ruediger P. Laubender, Sebastian Stintzing, Clemens Gießen, Christoph Schulz, Michael Haas, Ulrich Mansmann, Volker Heinemann

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer

    Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer gan Julian Walter Holch, Maximilian Demmer, Charlotte Lamersdorf, Marlies Michl, Christoph Schulz, Jobst C. von Einem, Dominik Paul Modest, Volker Heinemann

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan‐based randomized first‐line trial

    Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan‐based randomized first‐line trial gan Clemens Gießen, Ruediger P. Laubender, Ludwig Fischer von Weikersthal, Andreas Schalhorn, Dominik Paul Modest, Sebastian Stintzing, Michael Haas, Ulrich Mansmann, Volker Heinemann

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group

    Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal tran... gan Sebastian Stintzing, Christine Kapaun, Rüdiger P. Laubender, Andreas Jung, Jens Neumann, Dominik Paul Modest, Clemens Gießen, Nicolas Moosmann, Andreas Wollenberg, Thomas Kirchner, Volker Heinemann

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

    Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer gan Stephan Krüger, Marie-Louise Legenstein, Verena Rösgen, Michael Haas, Dominik Paul Modest, C. Benedikt Westphalen, Steffen Ormanns, Thomas Kirchner, Volker Heinemann, Stefan Holdenrieder, Stefan Boeck

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut)

    Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut) gan Dominik Paul Modest, Christoph Schulz, Ludwig Fischer von Weikersthal, D. Quietzsch, Jobst C. von Einem, Andreas Schalhorn, Ursula Vehling‐Kaiser, Rüdiger P. Laubender, Clemens Gießen, Sebastian Stintzing, Volker Heinemann

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

    FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumou... gan Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Ursula Vehling‐Kaiser, Elke Jäger, Tobias Heintges, Claude Stoll, Clemens Gießen, Dominik Paul Modest, Jens Neumann, Andreas Jung, Thomas Kirchner, Werner Scheithauer, Volker Heinemann

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial

    Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial gan Christopher Maximilian Arends, Savvina Dimitriou, Arndt Stahler, Raphael Hablesreiter, Paulina M. Strzelecka, Catarina M. Stein, Marlon Tilgner, Ryunosuke Saiki, Seishi Ogawa, Lars Bullinger, Dominik Paul Modest, Sebastian Stintzing, Volker Heinemann, Frédérik Damm

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors

    NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predomi... gan Christoph Schulz, Frank Kullmann, Volker Kunzmann, Martin Fuchs, Michael Geißler, Ursula Vehling‐Kaiser, Heribert Stauder, Axel Wein, Salah‐Eddin Al‐Batran, Thomas Kubin, Claus Schäfer, Sebastian Stintzing, Clemens Gießen, Dominik Paul Modest, Karsten Ridwelski, Volker Heinemann

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Prognostic and Predictive Molecular Markers in Cholangiocarcinoma

    Prognostic and Predictive Molecular Markers in Cholangiocarcinoma gan Sandra Pavicevic, Sophie Reichelt, Deniz Uluk, Isabella Lurje, Cornelius Engelmann, Dominik Paul Modest, Uwe Pelzer, Felix Krenzien, Nathanael Raschzok, Christian Benzing, Igor M. Sauer, Sebastian Stintzing, Frank Tacke, Wenzel Schöning, Moritz Schmelzle, Johann Pratschke, Georg Lurje

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

    Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial gan Jobst C. von Einem, Sylvia Peter, Christine Günther, Hans‐Dieter Volk, Gerald Grütz, Christoph Salat, Oliver J. Stoetzer, Peter J. Nelson, Marlies Michl, Dominik Paul Modest, Julian Walter Holch, Martin K. Angele, Christiane J. Bruns, Hanno Nieß, Volker Heinemann

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial

    Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial gan Jobst C. von Einem, Christine Guenther, Hans‐Dieter Volk, Gerald Grütz, Daniela Hirsch, Christoph Salat, Oliver J. Stoetzer, Peter J. Nelson, Marlies Michl, Dominik Paul Modest, Julian Walter Holch, Martin K. Angele, Christiane J. Bruns, Hanno Nieß, Volker Heinemann

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

    Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorect... gan Dominik Paul Modest, Ingrid Ricard, Volker Heinemann, S. Hegewisch-Becker, Wolff Schmiegel, Rainer Porschen, Sebastian Stintzing, Ullrich Graeven, Dirk Arnold, Ludwig Fischer von Weikersthal, Clemens Gießen-Jung, Arndt Stahler, Hans‐Joachim Schmoll, Andreas Jung, Thomas Kirchner, Andrea Tannapfel, Anke Reinacher‐Schick

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumors in Metastatic Colorectal Cancer

    Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumo... gan Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, S. Held, Markus Möhler, Andreas Jung, Thomas Kirchner, Volker Heinemann

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

    Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306) gan Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christoph Kahl, G. Seipelt, Frank Kullmann, Werner Scheithauer, Markus Moehler, Julian Walter Holch, Jobst C. von Einem, Swantje Held, Volker Heinemann

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    O-9 Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial

    O-9 Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUN... gan Gerald W. Prager, Julien Taı̈eb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Élez, F. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gábor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Nadia Amellal, Hafeez Hassan, Donia Skanji, Josep Tabernero

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.

    Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the... gan Julien Taı̈eb, Gerald W. Prager, Marwan Fakih, Fortunato Ciardello, Eric Van Cutsem, Elena Élez, Felipe Melo Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gábor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Lucas Roby, Valentine Barboux, Nadia Amellal, Josep Tabernero

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

    FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial gan Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Edin Al-Batran, Tobias Heintges, Christoph Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Markus Moehler, Werner Scheithauer, Swantje Held, Lisa Miller‐Phillips, Dominik Paul Modest, Andreas Jung, Thomas Kirchner, Sebastian Stintzing

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: